Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS

Journal of Virology

Volumn 84, Issue 16, 2010, Pages 8141-8152

  Guerra, Susana ^a,b   González, José Manuel ^a   Climent, Núria ^d   Reyburn, Hugh ^c   López Fernández, Luis A ^a,e   Nájera, José L ^a   Gómez, Carmen E ^a   García, Felipe ^d   Gatell, José M ^d   Gallart, Teresa ^d   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c CSIC   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR8; GLYCOPROTEIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN A5; HLA DR ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 2; JANUS KINASE 1; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MODIFIED VACCINIA VIRUS ANKARA B VACCINE; PROTEIN MICA; RECOMBINANT VACCINE; STAT PROTEIN; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CYTOKINE RELEASE; CYTOTOXIC LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; VACCINIA;

EID: 77954994086     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00749-10     Document Type: Article

References (67)

1. Albert, M. L., M. Jegathesan, and R. B. Darnell. 2001. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat. Immunol. 2:1010-1017.
2. Alcamí, A., J. A. Symons, P. D. Collins, T. J. Williams, and G. L. Smith. 1998. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J. Immunol. 160:624-633.
3. Reference deleted.
4. Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396.
5. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245-252.
6. Bauer, S., V. Groh, J. Wu, A. Steinle, J. H. Phillips, L. L. Lanier, and T. Spies. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727-729.
7. Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. 57:289-300.
8. Blanchard, T. J., A. Alcamí, P. Andrea, and G. L. Smith. 1998. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79(Pt. 5):1159-1167.
9. Chisholm, S. E., and H. T. Reyburn. 2006. Recognition of vaccinia virus-infected cells by human natural killer cells depends on natural cytotoxicity receptors. J. Virol. 80:2225-2233.
10. Choi, Y. K., B. A. Fallert, M. A. Murphey-Corb, and T. A. Reinhart. 2003. Simian immunodeficiency virus dramatically alters expression of homeostatic chemokines and dendritic cell markers during infection in vivo. Blood 101:1684-1691.
11. Cicala, C., J. Arthos, S. M. Selig, G. Dennis, Jr., D. A. Hosack, D. Van Ryk, M. L. Spangler, T. D. Steenbeke, P. Khazanie, N. Gupta, J. Yang, M. Daucher, R. A. Lempicki, and A. S. Fauci. 2002. HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication. Proc. Natl. Acad. Sci. U. S. A. 99:9380-9385.
12. Corbett, M., W. M. Bogers, J. L. Heeney, S. Gerber, C. Genin, A. Didierlaurent, H. Oostermeijer, R. Dubbes, G. Braskamp, S. Lerondel, C. E. Gómez, M. Esteban, R. Wagner, I. Kondova, P. Mooij, S. Balla-Jhagjhoorsingh, N. Beenhakker, G. Koopman, S. van der Burg, J. P. Kraehenbuhl, and A. Le Pape. 2008. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc. Natl. Acad. Sci. U. S. A. 105:2046-2051.
13. Delaloye, J., T. Roger, Q. G. Steiner-Tardivel, D. Le Roy, M. Knaup Reymond, S. Akira, V. Petrilli, C. E. Gómez, B. Perdiguero, J. Tschopp, G. Pantaleo, M. Esteban, and T. Calandra. 2009. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog. 5:e1000480.
14. Didierlaurent, A., J. C. Ramirez, M. Gherardi, S. C. Zimmerli, M. Graf, H. A. Orbea, G. Pantaleo, R. Wagner, M. Esteban, J. P. Kraehenbuhl, and J. C. Sirard. 2004. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine 22:3395-3403.
15. Drillien, R., D. Spehner, A. Bohbot, and D. Hanau. 2000. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology 268:471-481.
16. Gallego-Gómez, J. C., C. Risco, D. Rodríguez, P. Cabezas, S. Guerra, J. L. Carrascosa, and M. Esteban. 2003. Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells. J. Virol. 77:10606-10622.
17. García, F., M. Plana, C. Vidal, A. Cruceta, W. A. O'Brien, G. Pantaleo, T. Pumarola, T. Gallart, J. M. Miro, and J. M. Gatell. 1999. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 13:F79-F86.
18. Gherardi, M. M., J. L. Najera, E. Pérez-Jiménez, S. Guerra, A. Garcia-Sastre, and M. Esteban. 2003. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J. Virol. 77:7048-7057.
19. Gherardi, M. M., J. C. Ramirez, D. Rodríguez, J. R. Rodríguez, G. Sano, F. Zavala, and M. Esteban. 1999. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J. Immunol. 162:6724-6733.
20. Gómez, C. E., J. L. Najera, E. Domingo-Gil, L. Ochoa-Callejero, G. Gonzalez-Aseguinolaza, and M. Esteban. 2007. Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J. Gen. Virol. 88:2473-2478.
21. Gómez, C. E., J. L. Najera, E. P. Jimenez, V. Jimenez, R. Wagner, M. Graf, M. J. Frachette, P. Liljestrom, G. Pantaleo, and M. Esteban. 2007. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 25:2863-2885.
22. Gómez, C. E., J. L. Najera, V. Jimenez, K. Bieler, J. Wild, L. Kostic, S. Heidari, M. Chen, M. J. Frachette, G. Pantaleo, H. Wolf, P. Liljestrom, R. Wagner, and M. Esteban. 2007. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 25:1969-1992.
23. Gómez, C. E., J. L. Najera, M. Krupa, and M. Esteban. 2008. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther. 8:97-120.
24. González, S., V. Groh, and T. Spies. 2006. Immunobiology of human NKG2D and its ligands. Curr. Top. Microbiol. Immunol. 298:121-138.
25. + T-cell migration provides a mechanism for lymphadenopathy. J. Virol. 83:5765-5772.
26. Groh, V., R. Rhinehart, J. Randolph-Habecker, M. S. Topp, S. R. Riddell, and T. Spies. 2001. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2:255-260.
27. Groh, V., J. Wu, C. Yee, and T. Spies. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734-738.
28. Gudmundsdotter, L., C. Nilsson, A. Brave, B. Hejdeman, P. Earl, B. Moss, M. Robb, J. Cox, N. Michael, M. Marovich, G. Biberfeld, E. Sandström, and B. Wahren. 2009. Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite preexisting vaccinia immunity. Vaccine 27:4468-4474.
29. Guerra, S., L. A. Lopez-Fernandez, R. Conde, A. Pascual-Montano, K. Harshman, and M. Esteban. 2004. Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J. Virol. 78:5820-5834.
30. Guerra, S., L. A. Lopez-Fernandez, M. A. Garcia, A. Zaballos, and M. Esteban. 2006. Human gene profiling in response to the active protein kinase, interferon-induced serine/threonine protein kinase (PKR), in infected cells. Involvement of the transcription factor ATF-3 IN PKR-induced apoptosis. J. Biol. Chem. 281:18734-18745.
31. Guerra, S., L. A. Lopez-Fernandez, A. Pascual-Montano, M. Munoz, K. Harshman, and M. Esteban. 2003. Cellular gene expression survey of vaccinia virus infection of human HeLa cells. J. Virol. 77:6493-6506.
32. Guerra, S., L. A. Lopez-Fernandez, A. Pascual-Montano, J. L. Najera, A. Zaballos, and M. Esteban. 2006. Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells. J. Virol. 80:985-998.
33. Guerra, S., J. L. Najera, J. M. Gonzalez, L. A. Lopez-Fernandez, N. Climent, J. M. Gatell, T. Gallart, and M. Esteban. 2007. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J. Virol. 81:8707-8721.
34. Harrop, R., N. Connolly, I. Redchenko, J. Valle, M. Saunders, M. G. Ryan, K. A. Myers, N. Drury, S. M. Kingsman, R. E. Hawkins, and M. W. Carroll. 2006. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin. Cancer Res. 12:3416-3424.
35. Hochstein-Mintzel, V., H. C. Huber, and H. Stickl. 1972. Oral and nasal immunization with Poxvirus vacciniae. 3. Animal experiments. Zentralbl. Bakteriol. Orig. B 156:30-96.
36. Hsu, H., J. Xiong, and D. V. Goeddel. 1995. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 81:495-504.
37. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2009. AIDS epidemic update: November 2009. Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland. http://www.unaids.org/cn/KnowledgeCentre/HIVData/EpiUpdate/ EpiUpdArchive/2009/default.asp.
38. Kloss, M., P. Decker, K. M. Baltz, T. Baessler, G. Jung, H. G. Rammensee, A. Steinle, M. Krusch, and H. R. Salih. 2008. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. J. Immunol. 181:6711-6719.
39. Lehmann, M. H., W. Kastenmuller, J. D. Kandemir, F. Brandt, Y. Suezer, and G. Sutter. 2009. Modified vaccinia virus Ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J. Virol. 83:2540-2552.
40. León, B., and C. Ardavin. 2008. Monocyte migration to inflamed skin and lymph nodes is differentially controlled by L-selectin and PSGL-1. Blood 111:3126-3130.
41. Liu, L., R. Chavan, and M. B. Feinberg. 2008. Dendritic cells are preferentially targeted among hematolymphocytes by modified vaccinia virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol. 9:15.
42. Maasho, K., J. Opoku-Anane, A. I. Marusina, J. E. Coligan, and F. Borrego. 2005. NKG2D is a costimulatory receptor for human naive CD8+ T cells. J. Immunol. 174:4480-4484.
43. Matsukawa, A., C. M. Hogaboam, N. W. Lukacs, and S. L. Kunkel. 2000. Chemokines and innate immunity. Rev. Immunogenet. 2:339-358.
44. Mayr, A., H. Stickl, H. K. Muller, K. Danner, and H. Singer. 1978. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl. Bakteriol. B 167:375-390.
45. Mellman, I., and R. M. Steinman. 2001. Dendritic cells: specialized and regulated antigen processing machines. Cell 106:255-258.
46. Mooij, P., S. S. Balla-Jhagjhoorsingh, G. Koopman, N. Beenhakker, P. van Haaften, I. Baak, I. G. Nieuwenhuis, I. Kondova, R. Wagner, H. Wolf, C. E. Gómez, J. L. Najera, V. Jimenez, M. Esteban, and J. L. Heeney. 2008. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvi- rus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J. Virol. 82:2975-2988.
47. Moretta, A. 2002. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat. Rev. Immunol. 2:957-964.
48. Moretta, L., R. Biassoni, C. Bottino, M. C. Mingari, and A. Moretta. 2002. Natural killer cells: a mystery no more. Scand. J. Immunol. 55:229-232.
49. Moss, B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. U. S. A. 93:11341-11348.
50. Moss, B., M. W. Carroll, L. S. Wyatt, J. R. Bennink, V. M. Hirsch, S. Goldstein, W. R. Elkins, T. R. Fuerst, J. D. Lifson, M. Piatak, N. P. Restifo, W. Overwijk, R. Chamberlain, S. A. Rosenberg, and G. Sutter. 1996. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med. Biol. 397:7-13.
51. Nociari, M. M., A. Shalev, P. Benias, and C. Russo. 1998. A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J. Immunol. Methods 213:157-167.
52. Pacheco, R., J. M. Martinez-Navio, M. Lejeun e, N. Climent, H. Oliva, J. M. Gatell, T. Gallart, J. Mallol, C. Lluis, and R. Franco. 2005. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc. Natl. Acad. Sci. U. S. A. 102:9583-9588.
53. Pérez-Jiménez, E., G. Kochan, M. M. Gherardi, and M. Esteban. 2006. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes Infect. 8:810-822.
54. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, M. Benenson, S. Gurunathan, J. Tartaglia, J. G. McNeil, D. P. Francis, D. Stablein, D. L. Birx, S. Chunsuttiwat, C. Khamboonruang, P. Thongcharoen, M. L. Robb, N. L. Michael, P. Kunasol, and J. H. Kim. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
55. Ridge, J. P., F. Di Rosa, and P. Matzinger. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474-478.
56. Risco, C., J. R. Rodríguez, W. Demkowicz, R. Heljasvaara, J. L. Carrascosa, M. Esteban, and D. Rodríguez. 1999. The vaccinia virus 39-kDa protein forms a stable complex with the p4a/4a major core protein early in morphogenesis. Virology 265:375-386.
57. Rodríguez, D., M. Esteban, and J. R. Rodríguez. 1995. Vaccinia virus A17L gene product is essential for an early step in virion morphogenesis. J. Virol. 69:4640-4648.
58. Rodriguez, D., J. R. Rodríguez, J. F. Rodríguez, D. Trauber, and M. Esteban. 1989. Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. Proc. Natl. Acad. Sci. U. S. A. 86:1287-1291.
59. Rubio, V., T. B. Stuge, N. Singh, M. R. Betts, J. S. Weber, M. Roederer, and P. P. Lee. 2003. Ex vivo identification, isolation and analysis of tumorcytolytic T cells. Nat. Med. 9:1377-1382.
60. Sandström, E., C. Nilsson, B. Hejdeman, A. Brave, G. Bratt, M. Robb, J. Cox, T. Vancott, M. Marovich, R. Stout, S. Aboud, M. Bakari, K. Pallangyo, K. Ljungberg, B. Moss, P. Earl, N. Michael, D. Birx, F. Mhalu, B. Wahren, and G. Biberfeld. 2008. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis. 198:1482-1490.
61. Schneider, J., S. C. Gilbert, T. J. Blanchard, T. Hanke, K. J. Robson, C. M. Hannan, M. Becker, R. Sinden, G. L. Smith, and A. V. Hill. 1998. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:397-402.
62. Seet, B. T., J. B. Johnston, C. R. Brunetti, J. W. Barrett, H. Everett, C. Cameron, J. Sypula, S. H. Nazarian, A. Lucas, and G. McFadden. 2003. Poxviruses and immune evasion. Annu. Rev. Immunol. 21:377-423.
63. Seet, B. T., and G. McFadden. 2002. Viral chemokine-binding proteins. J. Leukoc. Biol. 72:24-34.
64. Smyth, G. K. 2004. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3:Article3.
65. Sutter, G., and C. Staib. 2003. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr. Drug Targets Infect. Disord. 3:263-271.
66. Verneris, M. R., M. Karami, J. Baker, A. Jayaswal, and R. S. Negrin. 2004. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103:3065-3072.
67. Waibler, Z., M. Anzaghe, H. Ludwig, S. Akira, S. Weiss, G. Sutter, and U. Kalinke. 2007. Modified vaccinia virus Ankara induces Toll-like receptorindependent type I interferon responses. J. Virol. 81:12102-12110.